InVitria –Performance. Defined.

InVitria, a division of Ventria Bioscience, was founded with the goal of providing the biotechnology industry with innovative products to improve cell culture and biomanufacturing. InVitria does this by allowing customers to eliminate animal components from their cell-based processes. Removing these components helps improve consistency, safety and efficiency. InVitria’s products are recombinant proteins that are manufactured in our manufacturing facility in Junction City, Kansas. These products have many uses across the life science industry including in regenerative medicine, cellular therapy, biomanufacturing, vaccines, diagnostics and medical devices.

Animal-components such as fetal bovine serum (FBS), bovine and human serum albumin, and bovine and human transferrin have been popular ingredients in many biological processes, but in the 1990’s scientists began searching for ways to remove serum and other animal products due to concerns about product quality, safety and animal stewardship. Animal products are undesirable because they pose a risk of transmitting infectious agents such as prions (Mad Cow Disease) and virus (HIV). In addition, animal components and blood derived products are undefined leading to high batch-to-batch variation. For these reasons, the Food and Drug Administration (FDA), European Medicines Agency (EMA) and other regulatory bodies discourage use of these animal components.

To date, InVitria has developed and commercialized eight recombinant proteins and cell culture media supplements. InVitria’s product development team has an active program to expand this product line based on customer needs.

At InVitria, we are proud of our team and our partnerships.

InVitria’s team is committed to providing innovative solutions to the most pressing cell culture challenges today.

“Helping customers integrate these animal component free products to improve their processes and reach their commercial objectives is what excites me about InVitria”

– Steve Pettit, Ph.D. Director, Cell Culture

“I like working with our customer auditors who are responsible for approving InVitria as a vendor. They come from some of the most successful biopharmaceutical and life science companies in the world, so their expectations are high. Our expectations are also high and that leads to a successful outcome.”

– Pat Smith, Director, Quality

As a Division of Ventria Bioscience, InVitria has access to Ventria’s Board of Directors and their expertise and successful history. These leaders include:

• a member of the National Academies of Science and 2003 Biotechnology Heritage Award Winner,
• former Chairman and CEO of the largest plant biotechnology company in the world,
• two founders of Chiron Corporation (now Novartis),
• former President of Johnson & Johnson’s diagnostics business,
• Chairman of PRA International, a leading clinical trial CRO,
• the former President of millipore’s Bioscience Division, and
• two General Partners of leading healthcare venture capital firms.